EE200300393A - Uus besoüülguanidiini sool - Google Patents
Uus besoüülguanidiini soolInfo
- Publication number
- EE200300393A EE200300393A EEP200300393A EEP200300393A EE200300393A EE 200300393 A EE200300393 A EE 200300393A EE P200300393 A EEP200300393 A EE P200300393A EE P200300393 A EEP200300393 A EE P200300393A EE 200300393 A EE200300393 A EE 200300393A
- Authority
- EE
- Estonia
- Prior art keywords
- salt
- sup
- besoylguanidine
- new
- hydrates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10106970A DE10106970A1 (de) | 2001-02-15 | 2001-02-15 | Neues Benzoylguanidinsalz |
| PCT/EP2002/001535 WO2002064563A1 (de) | 2001-02-15 | 2002-02-14 | Neues benzoylguanidinsalz |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200300393A true EE200300393A (et) | 2003-12-15 |
Family
ID=7674094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200300393A EE200300393A (et) | 2001-02-15 | 2002-02-14 | Uus besoüülguanidiini sool |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20080025919A1 (sl) |
| EP (1) | EP1362030B1 (sl) |
| JP (3) | JP4408626B2 (sl) |
| KR (1) | KR100862176B1 (sl) |
| CN (1) | CN1222510C (sl) |
| AT (1) | ATE553078T1 (sl) |
| AU (1) | AU2002250939B2 (sl) |
| BG (1) | BG66330B1 (sl) |
| BR (1) | BR0207867A (sl) |
| CA (1) | CA2434829C (sl) |
| CY (1) | CY1112878T1 (sl) |
| CZ (1) | CZ303277B6 (sl) |
| DE (1) | DE10106970A1 (sl) |
| DK (1) | DK1362030T3 (sl) |
| EA (1) | EA006245B1 (sl) |
| EC (1) | ECSP034708A (sl) |
| EE (1) | EE200300393A (sl) |
| ES (1) | ES2385472T3 (sl) |
| HK (1) | HK1064093A1 (sl) |
| HR (1) | HRP20030653B1 (sl) |
| HU (1) | HU230035B1 (sl) |
| IL (1) | IL156934A (sl) |
| NO (1) | NO20033299D0 (sl) |
| NZ (1) | NZ528081A (sl) |
| PL (1) | PL213300B1 (sl) |
| PT (1) | PT1362030E (sl) |
| RS (1) | RS52014B (sl) |
| SI (1) | SI1362030T1 (sl) |
| SK (1) | SK287830B6 (sl) |
| UA (1) | UA74625C2 (sl) |
| WO (1) | WO2002064563A1 (sl) |
| ZA (1) | ZA200305365B (sl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10106970A1 (de) * | 2001-02-15 | 2002-08-29 | Boehringer Ingelheim Pharma | Neues Benzoylguanidinsalz |
| DE10144030A1 (de) * | 2001-09-07 | 2003-03-27 | Boehringer Ingelheim Pharma | Verbesserung der lokalen Verträglichkeit bei intravenöser Verabreichung von 4-(4-(2-Pyrrolylcarbonyl-1-piperazinyl)-3-trifluormethyl-benzoylguanidin |
| US6982256B2 (en) | 2001-09-07 | 2006-01-03 | Boehringer Ingelheim Pharma Kg | Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration |
| CA2730116A1 (en) * | 2008-07-08 | 2010-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidinyl and piperidinyl compounds useful as nhe-1 inhibitors |
| WO2015160820A1 (en) * | 2014-04-14 | 2015-10-22 | The University Of Memphis | Wireless analog passive sensors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19601303A1 (de) * | 1996-01-16 | 1997-07-17 | Boehringer Ingelheim Kg | Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln |
| US6323207B1 (en) * | 1998-09-22 | 2001-11-27 | Boehringer Ingelheim Pharma Kg | Benzoylguanidine derivatives |
| DE19843489B4 (de) * | 1998-09-22 | 2006-12-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Benzoylguanidin-Abkömmlinge mit vorteilhaften Eigenschaften, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln, sowie diese enthaltende pharmazeutische Zubereitung |
| US6730678B2 (en) * | 2001-02-15 | 2004-05-04 | Boehringer Ingelheim Pharma Kg | Benzoylguanidine salt and hydrates thereof |
| DE10106970A1 (de) * | 2001-02-15 | 2002-08-29 | Boehringer Ingelheim Pharma | Neues Benzoylguanidinsalz |
-
2001
- 2001-02-15 DE DE10106970A patent/DE10106970A1/de not_active Ceased
-
2002
- 2002-02-14 SK SK1020-2003A patent/SK287830B6/sk not_active IP Right Cessation
- 2002-02-14 CZ CZ20032210A patent/CZ303277B6/cs not_active IP Right Cessation
- 2002-02-14 IL IL15693402A patent/IL156934A/en not_active IP Right Cessation
- 2002-02-14 AU AU2002250939A patent/AU2002250939B2/en not_active Ceased
- 2002-02-14 EA EA200300771A patent/EA006245B1/ru not_active IP Right Cessation
- 2002-02-14 CA CA002434829A patent/CA2434829C/en not_active Expired - Fee Related
- 2002-02-14 RS YU61503A patent/RS52014B/sr unknown
- 2002-02-14 CN CNB028049926A patent/CN1222510C/zh not_active Expired - Fee Related
- 2002-02-14 PL PL362129A patent/PL213300B1/pl unknown
- 2002-02-14 PT PT02719831T patent/PT1362030E/pt unknown
- 2002-02-14 EP EP02719831A patent/EP1362030B1/de not_active Expired - Lifetime
- 2002-02-14 JP JP2002564496A patent/JP4408626B2/ja not_active Expired - Fee Related
- 2002-02-14 ES ES02719831T patent/ES2385472T3/es not_active Expired - Lifetime
- 2002-02-14 UA UA2003098454A patent/UA74625C2/uk unknown
- 2002-02-14 SI SI200230982T patent/SI1362030T1/sl unknown
- 2002-02-14 DK DK02719831.6T patent/DK1362030T3/da active
- 2002-02-14 NZ NZ528081A patent/NZ528081A/en not_active IP Right Cessation
- 2002-02-14 KR KR1020037010723A patent/KR100862176B1/ko not_active IP Right Cessation
- 2002-02-14 BR BR0207867-8A patent/BR0207867A/pt active Pending
- 2002-02-14 HU HU0303027A patent/HU230035B1/hu not_active IP Right Cessation
- 2002-02-14 WO PCT/EP2002/001535 patent/WO2002064563A1/de active IP Right Grant
- 2002-02-14 AT AT02719831T patent/ATE553078T1/de active
- 2002-02-14 EE EEP200300393A patent/EE200300393A/xx unknown
-
2003
- 2003-07-11 ZA ZA200305365A patent/ZA200305365B/en unknown
- 2003-07-22 NO NO20033299A patent/NO20033299D0/no not_active Application Discontinuation
- 2003-07-29 EC EC2003004708A patent/ECSP034708A/es unknown
- 2003-08-06 BG BG108065A patent/BG66330B1/bg active Active
- 2003-08-13 HR HRP20030653AA patent/HRP20030653B1/xx not_active IP Right Cessation
-
2004
- 2004-09-08 HK HK04106807A patent/HK1064093A1/xx not_active IP Right Cessation
-
2007
- 2007-08-21 US US11/842,941 patent/US20080025919A1/en not_active Abandoned
-
2008
- 2008-06-06 US US12/134,245 patent/US20080241077A1/en not_active Abandoned
-
2009
- 2009-07-15 JP JP2009166773A patent/JP5745215B2/ja not_active Expired - Fee Related
-
2012
- 2012-07-06 CY CY20121100605T patent/CY1112878T1/el unknown
-
2013
- 2013-03-08 JP JP2013047091A patent/JP2013107906A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ598461A (en) | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases | |
| SE9903760D0 (sv) | New compounds | |
| IL165264A (en) | Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases | |
| NO20025601L (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
| MX2010006260A (es) | Composiciones orales de abt-263 para tratar cancer. | |
| SE9904176D0 (sv) | New use | |
| NZ585085A (en) | Method of treating arthritis using arylsulfonamide compounds | |
| NO20021328L (no) | Pyrazolopyrimidier som terapeutiske midler | |
| MY134110A (en) | Combinations of reboxetine and neuroleptic agents | |
| IL165262A (en) | Kinase inhibitors and pharmaceutical compositions containing them | |
| DE60226729D1 (de) | Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| GB0124933D0 (en) | Chemical compounds | |
| BR0317020A (pt) | Derivados de hidroxietilamina para o tratamento de doença de alzheimer | |
| NO20051966L (no) | Nye pyrimidinamidderivater og anvendelse derav | |
| DE60314013D1 (de) | 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten | |
| ATE341545T1 (de) | Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase | |
| ATE287886T1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer | |
| EE200300393A (et) | Uus besoüülguanidiini sool | |
| MXPA04005484A (es) | Procedimiento de preparacion de derivados de equinocandina. | |
| RU2003115431A (ru) | Новые применения объединенных агонистов 5-нт1а и ингибиторов обратного захвата серотонина | |
| DE60103034D1 (de) | Neue phenylheteroalkylamin-derivate | |
| SE0403118D0 (sv) | New compounds 2 | |
| ATE293591T1 (de) | Neue n-(2-phenyl-3-aminopropyl)naphtamide | |
| ATE511842T1 (de) | Kombinationstherapie zur behandlung von erhöhter miktionsfrequenz, akutem harndrang und inkontinenz | |
| DE60215525D1 (de) | Kombination aus quetiapin und zolmitriptan |